



LACCOG

IMPACTING
LATIN AMERICAN
LIVES THROUGH
CANCER RESEARCH

2019 ANNUAL REPORT

TABLE OF CONTENTS

01 LACOG EXECUTIVE DIRECTOR MESSAGE / 04

02 LACOG CHAIR MESSAGE / 05

03 ABOUT LACOG / 06

04 HEADQUARTERS / 07

05 LACOG MEMBERS / 08

06 LACOG INFOGRAPHIC / 10

07 OUR PARTNERS / 12

08 LACOG NEW VISUAL IDENTITY / 14

09 LUNG GROUP / 19

10 GENITOURINARY GROUP / 23

11 RADIATION ONCOLOGY GROUP / 27

12 NEURO ONCOLOGY GROUP / 31

13 HEAD AND NECK GROUP / 35

14 GYNECOLOGICAL GROUP / 39

15 BREAST GROUP / 43

16 GASTRO-INTESTINAL GROUP / 47

17 CLINICAL TRIALS / 50

18 PUBLICATIONS / 54

19 CONFERENCES AND EVENTS / 58

20 THE CURE PROJECT / 64

01

LACOG EXECUTIVE DIRECTOR MESSAGE



The achievements reached together and collaboratively by the whole LACOG community of investigators must be a reason for great pride to all of us. We began, 11 years ago, to pursue a dream that would place Latin-American investigators into the scenario of international clinical research, answering important questions to our reality. The challenges so far have been enormous, and there are many of them still to come, but it is incontestable that we are building a credible platform, supported by the qualified effort and dedication of our colleagues from all over the continent. An integration that has become even closer among the countries in our region remains a key purpose for the next years.

We already have a consist history in the development, conduction and publication of epidemiological studies. We have a great amount of patients participating in the studies, a number even bigger of investigators, and the most important, more trials initiated by LACOG investigators, assuring a path that, albeit challenging, has been solidly walked. It is also fundamental that we acknowledge the support from all of our partners so far, the industry, institutions, collaborative international and regional groups which we learn everyday and will keep working with.

At last, we have to highlight the professional and competent structure of the central office in Porto Alegre coordinated by Gustavo Werutsky, which is undoubtedly one of the greatest achievements for LACOG so far, also representing a differential that assures us security along the way ahead of us. In this way, continuing our efforts, step by step, cooperating and working even more collaboratively, that I am sure that we shall build a future of accomplishments and opportunities for the whole LACOG community.

Dr. Carlos Barrios

02

LACOG CHAIR MESSAGE

It is with great pleasure that we present the first edition of LACOG Annual Report that highlights the most important activities of our group in the year of 2019. It has been now 11 years since LACOG (former name GLICO) was founded by Latin American investigators with the aim to organize a cooperative group for cancer research in our continent. We started in 2009 our first clinical trial in breast cancer (LACOG 0801), with the participation of Argentina, Brazil and Peru. Since then we have performed 19 observational studies and 14 clinical trials in different tumor types as well as several publications in international conferences and journals. LACOG is an Academic Research Organization and today we are more than 400 investigators in 194 Institution within 16 countries in Latin America. By working together we have been successful in overcoming all the challenges of developing a cooperative research group in Latin America and supporting Investigator Initiated Trials. In the last years we have built a professional structure, the LACOG Coordinating Office, which attends the demands of our projects and intergroup studies. LACOG is also dedicated to educational activities by organizing events in different tumor types, the yearly licensed Best of ASCO and Best of SABCS Brazil and collaborative AACR sessions to bring updated cancer research advances for the scientific community in Latin America. We believe philanthropy is vital to fundraise and support our academic research projects that have no commercial interest but are crucial for patients. The Projeto CURA, headed by Fernanda Schwyter, organized in 2019, fundraised activities such as TJCC panel, Best of ASCO Brazil Award and Dinner among others to finance LACOG research projects.

We thank our staff, members, partners, patients and donors for their support to LACOG mission to improve cancer research and patients cancer care in Latin America.

Dr. Gustavo Werutsky



03

ABOUT LACOG

LACOG - The Latin American Cooperative Oncology Group - is a non-profit organization, founded in 2009 by a group of Latin American medical oncologists interested in developing clinical research. This is the first multinational cooperative group in Latin America, exclusively dedicated to clinical and translational cancer research. LACOG currently has more than 400 investigators members, present in 194 institutions from 16 Latin American countries.

The group develops observational studies to describe the diagnosis, treatment and survival of cancer patients in several tumor types, and also performs clinical trials investigating new biomarkers, novel drugs and surgical or radiation therapy techniques.

LACOG has the aim to build a network of cancer investigators in Latin America and clinical trials in the region. LACOG collaborates with international groups, academic institutions and the biotechnological/pharmaceutical industry to promote and develop innovative studies for Latin American patients.



04

HEADQUARTERS

LACOG office is located at PUCRS university in Porto Alegre, Brazil. The office is responsible for assisting investigators to prepare a study concept and to perform the studies operational activities such as protocol development, management, monitoring, pharmacovigilance and statistics. Currently, LACOG team counts on 18 employees; among them are physicians, biomedical scientists, pharmacists, statisticians, IT and administrative analysts and professionals of communication working towards the development of clinical research in Latin America.

05

LACOG MEMBERS

The investigators are an essential part of LACOG. We are more than 400 members from all over Latin America collaborating in observational studies and clinical trials. LACOG offers the possibility of Latin American investigators to develop new studies and participate in regional and international cancer trials. Between 2018 and 2019, we had 132 new registered members, thus being the greatest number of registration since the group foundation in 2009.

ARGENTINA
27

BOLIVIA
02

BRAZIL
295

COLOMBIA
13

CHILE
10

COSTA RICA
04

CUBA
02

EL SALVADOR
01

ECUADOR
02

GUATEMALA
05

MEXICO
20

NICARAGUA
01

PANAMA
02

PERU
11

URUGUAY
02

VENEZUELA
03



06

LACOG INFOGRAPHIC



INVESTIGATORS
400



HOSPITALS
194



COUNTRIES
16

*Argentina, Brazil, Bolivia, Colombia, Chile,
Costa Rica, Cuba, El Salvador, Ecuador,
Guatemala, Mexico, Nicaragua, Panama,
Peru, Uruguay and Venezuela*



**MORE THAN
40**
PERFORMED AND
ONGOING STUDIES



**MORE THAN
5.000**
PATIENTS
PARTICIPATED IN
LACOG STUDIES



**MORE THAN
55**
ABSTRACTS
AND ARTICLES
PUBLISHED



**MORE THAN
20**
EDUCATIONAL
EVENTS

07

OUR PARTNERS

LACOG collaborates with national and international study groups, participating in the development and management of epidemiological studies and clinical trials.



LACOG IS MEMBER OF



08

LACOG NEW VISUAL IDENTITY

The brand LACOG was created in 2012, aiming to identify the first cooperative research group in Latin America. An update to the visual identity and communication strategy was developed to attend the group's new growing step. The rebrand of the LACOG logo has a modern design and we created a specific logo for each LACOG cancer group in different specialties – breast, lung, genitourinary, gynecological, head and neck, radiation, neurological and gastrointestinal.

The new communication plan has the goal of informing LACOG values - collaboration, innovation and credibility - positioning the group as a prime academic research organization in Latin America. The redesigned brand will standardise LACOG communication in events, study materials, newsletters, among other graphic materials. A new website is planned to be launched in 2020 with more information, graphics and with a new design.



old brand



new



variations

only symbol



symbol and lettering




symbol, lettering and tagline




brand groups





LACOG GROUPS





CHAIR MESSAGE

GBOT [Brazilian Group of Thoracic Oncology] was initially funded by a multidisciplinary group involved in lung cancer treatment, aiming to broaden scientific knowledge and education in the area of Thoracic Oncology.

The relationship between LACOG and GBOT has provided GBOT with the possibility of professionalizing the research structure and events organization as well as the website layout and members updating. Such partnership has generated several research projects, from preparation to its publication at national and international levels. Some of the studies opened by GBOT/LACOG include: LACOG 0116 (The LATINO Lung Study which is, in a prospective fashion, recruiting a minimum of 700 and a maximum of 800 patients with advanced NSCLC (Non-small cell lung cancer), including locally advanced disease with services in Argentina, Brazil, Chile, Colombia and Mexico); LACOG 0118 (observational cohort study, retrospective, which is collecting demographic and clinical data from patients diagnosed with advanced

NSCLC between January 2015 and December 2016); LACOG 0417 (retrospective analysis of NSCLC patients, who have brain metastasis), LACOG 0718 (prospective assessment of patient selection for brain prophylactic radiotherapy in NSCLC); LACOG 1918, (journey of the ALK positive patient in Brazil) and LACOG 2218 (chemotherapy-radiotherapy and immunotherapy with durvalumab for stage III NSCLC: Brazilian phase II study (PACIFIC BRAZIL).

The Group most recent publication, entitled Lung Cancer in Brazil, occurred in January for the Journal of Thoracic Oncology.

Dr. Clarissa Maria Cerqueira Mathias

LACOG Lung Cancer Group Chair

NOB - Núcleo de Oncologia da Bahia

Salvador, BA, Brazil



BOARD MEMBERS



Dr. Mauro Zukin

Vice-chair

Oncologia D'Or

Rio de Janeiro, RJ, Brazil

Dr. Clarissa Baldotto

Secretary

Oncologia D'Or

Rio de Janeiro, RJ, Brazil





CHAIR MESSAGE

The year of 2019 was intense to the GU team. We finalized the recruitment for LACOG 0415 study, which, in a pioneer way, evaluated the patients' prostate cancer treatment without the use of androgen deprivation. Another study on prostate cancer initiated to evaluate outcomes among patients treated by SUS (Brazilian public health system) and private health services (LACOG1818) had the main purpose of showing the differences of treatment between both national realities. Another international prospective epidemiological study on metastatic prostate cancer had its recruitment initiated this year (LACOG1818-IRONMAN).

The database for testicular cancer (LACOG0515) very much improved and shall have its data presented in 2020. We initiated a molecular epidemiological study on urothelial carcinoma (LACOG1518), our very first one involving Latin-American countries. Regarding locally advanced bladder cancer, a study evaluating the combination of immunotherapy and PARP inhibitor was approved (LACOG0219). A study was also approved for penile cancer due to the high incidence in Brazil (LACOG0218). Our relevance was confirmed with the partnership established with EORTC regarding the cooperation in the study that evaluates the combination of enzalutamide with or without radium 223 as first line for castration-resistant prostate cancer (PEACE3-LACOG0519). Several projects are being developed

for: localized prostate cancer, metastatic castration-resistant and castration-sensitive prostate cancer, metastatic kidney cancer and penile cancer. The scientific production culminated in the publication of scientific articles and the presentation of posters in international congresses. Partnerships with Brazilian societies of urology, pathology and oncology generated treatment consensus for bladder, kidney and penile cancers. The year of 2020 tends to be a year of many publications, studies and activities, in addition to the expansion to other sites in Latin America.



Dr. Diogo Assed Bastos

LACOG Genitourinary Group Chair

ICESP – Instituto do Câncer do Estado de São Paulo/
Hospital Sírio-Libanês

São Paulo, SP, Brazil

BOARD MEMBERS



Dr. Fernando Nunes

Secretary

Clion – Clínica de Oncologia

Salvador, BA, Brazil



Dr. Vinícius Carrera

Executive Director

Centro de Oncologia – Hospital Cardio-Pulmonar

Salvador, BA, Brazil



Dr. Diogo Rodrigues Rosa

Educational Director

Grupo Oncoclínicas RJ

Rio de Janeiro, RJ, Brazil



Dr. Andrey Soares

Scientific Director

Centro Paulista de Oncologia

São Paulo, SP, Brazil



CHAIR MESSAGE

During the year of 2019, many conquests were established by the LACOG Radiation group. Among them, we mention the following as the main ones:

1. The international launch of the randomized clinical trial named FRA.COM, which encompasses five continents and has an estimated number of 350 patients with complicated bone metastases.

2. We established that Dr. Gustavo Marta (ICESP/HSL) shall evaluate the aspects related to Radiotherapy for parallel publication of AMAZONA III study, Dr. Heloisa de Carvalho (ICESP/HSL) shall evaluate the aspects related to Radiotherapy for parallel publication of EVA 001 study and that Dr. Rafael Gadia (HSL, Brasília) shall evaluate the aspects related to Radiotherapy for parallel publication of LACOG 0116 study.

3. We developed a Textbook in partnership with novapublishers (2 volumes, <https://novapublishers.com/shop/cancer-management-in-latin-america-i-nasopharyngeal-to-renal-cancer> and <https://novapublishers.com/shop/cancer-management-in-latin-america-ii-melanoma-to-cost-effectiveness/>) regarding Cancer Management in Latin America. Those textbooks can be

accessed on the above mentioned websites and have the cooperation of approximately 100 radio-oncologists, clinical oncologists and surgeons from all over the world, mainly from Latin America.

LACOG is involved as an Institution to which some authors are bound to, as in my case.

4. We are currently working to gather funds for academic clinical research (as it is the greatest part of radiotherapy studies), together with the major companies in the area.

Dr. Maurício Fraga da Silva

LACOG Radiation Group Chair

Hospital Universitário de Santa Maria

Santa Maria, RS, Brazil



BOARD MEMBERS



Dr. Gustavo Nader Marta

Vice-chair

ICESP
Hospital Sírio-Libanês

São Paulo, SP, Brazil

Dr. Beatriz Amendola

Secretary

Innovative Cancer Institute

Miami, FL, USA





CHAIR MESSAGE

LACOG Neuro-Oncology Group was funded in 03/2019 aiming to complement the research in neuro-oncology patients. We organized a board of interested people and initiated the discussions on protocols to be developed in Brazil and Latin America. We are initiating a retrospective protocol on gliomas in the Brazilian population and there are other ongoing projects.

Dr. Camilla Akemi Felizardo Yamada
LACOG Neuro-Oncology Group Chair
Beneficência Portuguesa de São Paulo
São Paulo, SP, Brazil




BOARD MEMBERS



Dr. Fernando Maluf
Vice-chair
Beneficência Portuguesa de São Paulo
São Paulo, SP, Brazil

Dr. Suzana Maria Fleury Malheiros
Secretary
Hospital Israelita Albert Einstein
São Paulo, SP, Brazil





CHAIR MESSAGE

The Brazilian Group of Head and Neck Cancer / LACOG-HN has the mission of conducting the whole cycle of care involving the head and neck cancer in Brazil.

In 2019, the Group conducted activities regarding the four different fronts:

- 1) Professional Education;
- 2) Support to Patients;
- 3) Raising Population Awareness
- 4) Clinical Research.

Some of these activities:

Webmeetings discussing nutritional support to patients, immunotherapy and tumor boards; Annual Symposium in São Paulo; Forum of HNC Patients in SP in partnership with Oncoguia; HNC Regional Symposium in Vitória with launch of COOKBOOK – recipes book developed for patients who had HNC, coordinated by the nutritionist Olivia Podesta, partnered with group Nutrisdobem; presentation in the American Head and Neck Society Annual Meeting in Austin, regarding the study we conducted with the Brazilian population about their knowledge on HNC and its risk factors; postings on social media about HNC; biweekly blog of scientific articles updating. In clinical research, William William coordinated activities and monthly meetings in which study designs were discussed and

later submitted to development agencies/industries and international partnerships such as EORTC. An induction study, coordinated by Pedro de Marchi in Barretos, was initiated and shall be opened to other sites in 2020.

We did a lot in 2019. But there is a lot of work left to be done. Placing head and neck cancer in the national oncology agenda with events and dedicated studies is the GBCP/LACOG-HN mission.



Dr. Aline Lauda Freitas Chaves

LACOG Head and Neck Group Chair

DOM Oncologia

Divinópolis, MG, Brazil

BOARD MEMBERS



Dr. Luiz Paulo Kowalski

Vice-chair

A. C. Camargo Cancer Center


São Paulo, SP, Brazil

Dr. Gilberto de Castro Júnior

Secretary

ICESP- Instituto do Câncer do
Estado de São Paulo

São Paulo, SP, Brazil





CHAIR MESSAGE

The conclusion of the year of 2019 marks the growth of LACOG Gynecological oncology group. In its follow-up phase, the epidemiological EVITA study, which included more than 600 patients, specifically its analysis “Epidemiological and quality of life data of cervical cancer patients in Brazil: preliminary results of the prospective EVITA study (EVA001/LACOG 0215)” has been recently accepted for publication in RBGO.

The first clinical trial of the group, 2020 initiated with SIVs in several sites of the important phase II study “Palbociclib combined with letrozole after progression to second line chemotherapy for women with ER/PR-positive ovarian cancer”.

Focusing on phase III, the group initiates the first formal cooperation with GCIG in the SENTICOL III study. Already partnered with GOG, the plan is to expand the international cooperation.

Regarding social causes, together with CURA, the Group supports the necessary Brazil Free of Cervical Cancer Movement [Movimento Brasil Sem Câncer do Colo do Útero]. And 2020 promises even more!

Dr. Angélica Nogueira Rodrigues

LACOG Gynecological Group Chair

UFMG - Universidade Federal de Minas Gerais

Belo Horizonte, MG, Brazil



BOARD MEMBERS



Dr. Alfonso Dueñas Conzález

Vice-chair

Instituto Nacional de Cancerología

Instituto de Investigaciones
Biomedicas UNAM

Ciudad de México, DCMX, México

Dr. Aknar Freire de Carvalho Calabrich

Secretary

Clínica AMO - Assistência
Multidisciplinar em Oncologia

Salvador, BA, Brazil





CHAIR MESSAGE

The LACOG Breast aims to develop real world studies and clinical trials in Latin America as well as to collaborate with international intergroup studies to improve breast cancer care in the region. The group is currently performing the AMAZONA III study in collaboration with GBECAM Brazil and setting up the LATINA Breast study, which will be the most comprehensive registry of breast cancer in Latin America with 35 sites in 11 countries. We believe observational studies are critical to our region as limited data are available in breast cancer diagnosis and treatment. Such studies also offer an opportunity to investigators to work together uniting our group. In addition, we are collaborating with two ongoing phase III trials PALLAS and IMpassion030, which are evaluating CDK 4/6 and immunotherapy in early stage setting. LACOG Breast organizes annually the Conferência Brasileira de Câncer de Mama and the Best of SABCS Brazil where we discuss the most updated scientific advances in breast cancer. Our plan for the next year is to develop clinical trials with novel drugs especially in the (neo)adjuvant setting as locally advanced disease at diagnosis is the most common presentation in patients in Latin America and we want to improve cure rates for those patients.



Dr. Henry Gomez Moreno

LACOG Breast Group Chair

INEN - Instituto Nacional de Enfermedades Neoplásicas

Lima, Peru

BOARD MEMBERS



Dr. Max Senna Mano

Vice-chair

Hospital Sírio-Libanês

São Paulo, SP, Brazil

Dr. Cynthia Mayté Villareal Garza

Secretary

Centro de Cáncer de Mama – TecSalud
Instituto Nacional de Cancerología

Monterrey, México





CHAIR MESSAGE

The LACOG Gastro-intestinal group was created in 2019 and is composed by the board of directors of the Brazilian Gastrointestinal Tumors Group (GTG). Our aims are to develop studies on real-world data from our region and clinical trials to improve the outcomes of patients with gastrointestinal malignancies as well as to foster and offer educational activities.

Dr. Rachel Riechelmann

LACOG Gastro-Intestinal Chair

A.C. Camargo Câncer Center

São Paulo, SP, Brazil



BOARD MEMBERS



Dr. Anelisa Coutinho

Vice-chair

Clínica AMO – Assistência
Multidisciplinar em Oncologia

Salvador, BA, Brazil

Dr. Renata D'alpino Peixoto

Secretary

Hospital Alemão Oswaldo Cruz

São Paulo, SP, Brazil



17

CLINICAL TRIALS

LUNG	STUDY NAME	TYPE OF STUDY	SPONSOR / SUPPORT	TITLE	SAMPLE SIZE	COUNTRIES LATAM
	LACOG 0116 LATINO LUNG	Epidemiological	LACOG/ BMS, Pfizer	Prospective epidemiological study of metastatic Non Small Cell Lung Cancer (NSCLC) in Latin America	800 patients	Argentina, Brazil, Colombia, Mexico and Uruguay
	LACOG 0118 RELANCE	Epidemiological	LACOG, GBOT/ AstraZeneca	Retrospective epidemiological study of Locally Advanced Non Small Cell Lung Cancer	400 patients	Brazil
	LACOG 0417 CNS MTX	Epidemiological	LACOG/ GBOT	Retrospective Analysis of Patients with Non-Small Cell Lung Cancer with Brain Metastasis	385 patients	Brazil
	LACOG 1918 ALK registry	Epidemiological	LACOG, GBOT/ Takeda	Patient Journey with advanced lung cancer positive for ALK fusion in Brazil	70 to 100 patients	Brazil
	LACOG 0718 PCI Project	Clinical Trial	LACOG, GBOT	Prospective evaluation of patients decision aid questionnaire for prophylactic cranial irradiation (PCI) in Small Cell Lung Cancer (SCLC)	30 patients	Brazil
	LACOG 2218 PACIFIC BRAZIL	Clinical Trial	LACOG/ AstraZeneca	Intensified chemo-immuno-radiotherapy with durvalumab (MEDI4736) for stage III Non-Small Cell Lung Cancers (NSCLCs): a Brazilian Single Arm Phase II study (PACIFIC BRAZIL)	48 patients	Brazil

BREAST	STUDY NAME	TYPE OF STUDY	SPONSOR / SUPPORT	TITLE	SAMPLE SIZE	COUNTRIES LATAM
	LACOG 0615 LATINA Breast	Epidemiological	LACOG/ Roche	A study to observe patients characteristics, treatment patterns and outcomes in patients with newly diagnosed breast cancer in Latin America.	4.500 patients	Argentina, Brazil, Bolivia, Chile, Colombia, Costa Rica, Cuba, Ecuador, Guatemala, Mexico, Peru, Republica Dominicana Uruguay and Venezuela
	LACOG 0413 Male Breast Cancer	Epidemiological	EORTC	Clinical and biological characterization of Male Breast Cancer: an international EORTC, BIG, TBCRC and NABCG intergroup study.	533 patients	Brazil, Mexico and Peru
	GBECAM 0115 - AMAZONA III	Epidemiological	LACOG GBECAM / PRONON	Prospective evaluation of breast cancer at Brazilian institutions - Project AMAZONA III	3.000 patients	Brazil
	PALLAS	Clinical Trial	ABCSG ALLIANCE	A randomized phase III trial of palbociclib with adjuvant endocrine therapy versus endocrine therapy alone for hormone receptor positive (HR+)/ human epidermal growth factor receptor 2 (HER2)-negative early breast Cancer	4.600 patients	Mexico
	LACOG 2118 ALEXANDRA/ IMpassion 030	Clinical Trial	BIG AFT	A phase III, multicenter, randomized, open-label study comparing Atezolizumab (ANTI-PD-L1 ANTIBODY) in combination with adjuvant Anthracycline/ Taxane-based chemotherapy versus chemotherapy alone in patients with operable triple-negative breast cancer.	2.300 patients	Brazil and Mexico

	STUDY NAME	TYPE OF STUDY	SPONSOR / SUPPORT	TITLE	SAMPLE SIZE	COUNTRIES LATAM
GASTRO-INTESTINAL	LACOG/GTG 1318 - CCA	Epidemiological	LACOG, GTG	A multicenter retrospective database on prognostic and predictive factors in patients with squamous cell carcinoma of the anus.	300 patients	Brazil
	LACOG 0119 NET	Epidemiological	LACOG, GTG	A multicenter retrospective database on prognostic and predictive factors in patients with neuroendocrine tumors	300 patients	Brazil
GYNECOLOGICAL	LACOG 0215 EVITA	Epidemiological	LACOG/ Roche	Prospective evaluation of patients with uterine cervical cancer in Brazilian health institutions	800 patients	Brazil
	LACOG 1018 PALBO in Ovarian Cancer	Clinical Trial	LACOG/ Pfizer	Palbociclib plus letrozole combination after progression to second line chemotherapy for women with ER/PR-positive ovarian cancer	39 patients	Brazil
NEURO	LACOG 0619 Glioma Registry	Epidemiological	LACOG	Characterization of patients with diffuse gliomas in Brazil	300 patients	Brazil
RADIATION	LACOG 1618 Bone Metastasis Radiotherapy	Clinical Trial	LACOG	Radiotherapy with 5 fractions of 4 Gy or 10 fractions of 3 Gy versus 2 fractions of 8 Gy with a week interval in patients with complicated bone metastases: a randomized controlled multi-center	352 patients	Brazil

	STUDY NAME	TYPE OF STUDY	SPONSOR / SUPPORT	TITLE	SAMPLE SIZE	COUNTRIES LATAM
GENITOURINARY	LACOG 1518 Bladder Cancer Registry	Epidemiological	LACOG/ Janssen	Clinical-pathological Characterization and Outcomes of Metastatic Urothelial Cancer in Latin America: Retrospective and Translational Multicenter Database	204 patients	Brazil, Mexico, Argentina e Guatemala
	LACOG 0515 TESTICULAR REGISTRY	Epidemiological	LACOG	Multicentric database of patients with germ cell tumor with the purpose of clinical and pathological characterization and evaluation of cancer treatment outcomes	200 patients	Brazil
	LACOG 0217 IRONMAN	Epidemiological	LACOG/ Movember	Prostate Cancer Outcomes: An International Registry to Improve Outcomes in Men with Advanced Prostate Cancer	5.000 patients	Brazil
	LACOG 1818 Prostate Cancer Registry	Epidemiological	LACOG	Survival outcomes in metastatic prostate cancer in the Brazilian population - analysis of individual characteristics and treatment modalities in different national health institutions	590 patients	Brazil
	LACOG 0218 Hercules	Clinical Trial	LACOG/ MSD	A phase II trial of pembrolizumab combined with cisplatin-based chemotherapy as first-line systemic therapy in advanced penile cancer	33 patients	Brazil
	LACOG 0415 APA in Prostate Cancer	Clinical Trial	LACOG/ Janssen	Phase II randomized study of Abiraterone acetate plus ADT versus APALUTAMIDE versus Abiraterone and APALUTAMIDE in patients with advanced prostate cancer with non-castrate testosterone levels	126 patients	Brazil
	LACOG 0519 PEACE III	Clinical Trial	EORTC/ Bayer	A Randomized multicenter phase III trial comparing enzalutamide vs. a combination of Ra223 and enzalutamide in asymptomatic or mildly symptomatic castration resistant prostate cancer patients metastatic to bone. PEACE III	560 patients	Brazil

18

PUBLICATIONS

2019 was important to LACOG in terms of scientific production. With a total of 10 articles and 8 abstracts published, this is the biggest number of publications since the foundation of the group.

ARTICLES

Access to high-cost drugs for advanced breast cancer in Latin America, particularly trastuzumab

Ecancermedicalsecience. 2019 Jan 22;13:898.

Carlos Henrique Barrios, Tomás Reinert and Gustavo Werutsky

Locally advanced breast cancer in Brazil: current status and future perspectives

Ecancermedicalsecience. 2019 Jan 22;13:895.

Gustavo Werutsky, Paulo Nunes and Carlos Barrios

HPV Vaccination in Latin America: Global Challenges and Feasible Solutions

Am Soc Clin Oncol Educ Book. 2019 Jan;39:e45-e52.

Angelica Nogueira-Rodrigues

Characteristics and prognosis of stage I-III breast cancer subtypes in Brazil: The AMAZONA retrospective cohort study.

Breast. 2019 Apr;44:113-119

Sergio Daniel Simon, José Bines, Gustavo Werutsky, João Soares Nunes, Fernando Chalu Pacheco, José Getúlio Segalla, Andrea J.S. Gomes, Brigitte Marie H.R. Adam Van Eyll, Daniel Luiz Gimenes, Susanne Crocamo, Ruffo Freitas-Junior, Lissandra Dal Lago, Geraldo Silva Queiroz, Sérgio Jobim de Azevedo, Daniela Dornelles Rosa, Gilson Delgado, Giuliano Santos Borges, Yeni Verônica do Nascimento, Facundo Zaffaroni, Jeovany Martínez-Mesa, Carlos H.E. Barrios

PET-CT has low specificity for mediastinal staging of non-small-cell lung cancer in an endemic area for tuberculosis: a diagnostic test study (LACOG 0114).

BMC Cancer. 2019 May 23;19(1):487

Gustavo Werutsky, Bruno Hochegger, José Antônio Lopes de Figueiredo Pinto, Jeovany Martínez-Mesa, Mara Lise Zanini, Eduardo Herz Berdichevski, Eduardo Vilas, Vinícius Duval da Silva, Maria Teresa Ruiz Tsukazan, Arthur Vieira, Leandro Genehr Fritscher, Louise Hartmann, Marcos Alba, Guilherme Sartori, Cristina Matushita, Vanessa Bortolotto, Rayssa Ruszkowski do Amaral, Luís Carlos Anflor Junior, Facundo Zaffaroni, Carlos H. Barrios, Márcio Debiasi and Carlos Cezar Frietscher

TheLACOG-0415phaseIItrial:abirateroneacetate and ADT versus apalutamide versusabiraterone acetate and apalutamide inpatients with advanced prostate cancerwith non-castration testosterone levels

BMC Cancer. 2019; 19: 487.

Gustavo Werutsky, Fernando Cotait Maluf, Eduardo Henrique Cronemberger, Vinicius Carrera Souza, Suelen Patricia dos Santos Martins, Fábio Peixoto, Oren Smaletz, Fábio Schutz, Daniel Herchenhorn, Telma Santos, Flavio Mavignier Carcano, David Queiroz Muniz, Paulo R. S. Nunes Filho, Facundo Zaffaroni, Carlos Barrios and André Fay

Alternative Therapies to Bacillus Calmette-GuérinShortageforNonmuscleInvasiveBladder Cancer in Brazil and Other Underdeveloped Countries: Management Considerations

J Glob Oncol. 2019 Aug;5:1-9.

Marcelo Langer Wroclawski, Fabio A. Schutz, Jonathan Doyun Cha, and Andrey Soares

Advanced stage at diagnosis and worse clinicopathologic features in young woman with breast cancer. A sub-analysis of Brazilian population through the AMAZONA III study (GBECAM 0115).

J Glob Oncol. 2019 Nov;5:1-10

Maria Alice Franzoi, Daniela D. Rosa, Facundo Zaffaroni, Gustavo Werutsky, Sérgio Simon, José Bines, Carlos Barrios, Eduardo Cronemberger, Geraldo Silva Queiroz, Vladmir Cordeiro de Lima, Ruffo FreitasJúnior,José Couto, Karla Emerenciano, Heloísa Resende, Susanne Crocamo, Tomás Reinert, Brigitte Van Eyli, Yeni Nerón, Vanessa Dybal, Nicolas Lazaretti, Rita de Cassia Costamillan, Diocésio Alves Pinto de Andrade, Clarissa Mathias, Giovana Zerwes Vacaro, Giuliano Borges, Alessandra Morelle, Carlos Alberto Sampaio Filho, Max Mano, Pedro E. R. Liedke

Renal cell cancer treatment: an expert panel recommendation from the Latin American cooperative group-genitourinary and the Latin American renal cancer group: focus on surgery

Ther Adv Urol. 2019 Sep 9;11:1756287219872324

Stênio de Cássio Zequi, Walter Henriques da Costa, Fernando Korkes, Rodolfo Borges dos Reis, Wilson Francisco Schreiner Busato, Wagner Eduardo Matheus, Deusdedit Cortez Vieira da Silva Neto, Felipe de Almeida e Paula, Gustavo Franco Carvalhal, Lucas Nogueira, Roni de Carvalho Fernandes, Adriano Gonçalves e Silva, André Deeke Sasse, André P. Fay, Denis Leonardo Jardim, Diogo Assed Bastos, Diogo Augusto Rodrigues da Rosa, Evanius Wierman, Fabio Kater, Fabio A. Schutz, Fernando Cotait Maluf, Fernando Nunes Galvão de Oliveira, Igor Alexandre Protzner Morbeck, José Augusto Rinck, Karine Martins da Trindade, Manuel Caitano Maia, Vinicius Carrera Souza, Fernando Sabino Marques Monteiro, Andrey Soares

Cross-Cultural Validity Study of a Medical EducationLeadershipCompetenciesInstrument in Latin American Physicians: A Multinational Study

J Glob Oncol. 2019 Nov;5:1-9.

Max S. Mano, Rafaela Gomes, Gustavo Werutsky, Carlos H. Barrios, Gustavo Nader Marta, Cynthia Villarreal-Garza, Antonio Luiz Frasson, Cinthya Sternberg, Renan Clara, Sergio D. Simon, Fadil Çitaku, Marianne Waldrop, Claudio Violato, Don Zillioux and Yawar Hayat Khan

ABSTRACTS

Cross-cultural validation of a medical leadership competencies survey in Latin-American physicians: A multinational study.

ASCO 2019; J Clin Oncol 37, 2019 (suppl; abstr 10517), poster

Max S. Mano, Rafaela Gomes, Carlos H. Barrios, Gustavo Nader Marta, Cynthia Villarreal-Garza, Antonio Luiz Frasson, Cinthya Sternberg, Renan Clara, Sergio D. Simon, Gustavo Werutsky, and Fadil Çitaku.

Meta-analysis of randomized clinical trials (RCT) for the adjuvant treatment of renal cell carcinoma (RCC) with vascular endothelial growth factor receptor tyrosine-kinase inhibitors (VEGFR TKIs).

ASCO 2019; J Clin Oncol 37, 2019 15_suppl.4579, published online only

Daniel Vargas Almeida, Cleyton Z. Oliveira, Andrey Soares, RODRIGO COUTINHO MARIANO, Denis L Jardim, Diogo Assed Bastos, Fernando C. Maluf, Gustavo Werutsky, Fernando Sabino M Monteiro, Vinicius Carrera Souza, Guillermo de Velasco, Andre P. Fay, Andre Deeke Sasse, Fabio A. B. Schutz.

Social and economic impact of cervical cancer in Brazil: analysis of EVA/EVITA cohort study (LACOG 0215)

IGCS 2019; 42, oral presentation

Angelica Nogueira-Rodrigues, Andréia Cristina de Melo, Aknar Freire de Carvalho Calabrich, Eduardo Cronenberger, Kátia Luz Torres, Fernanda Damian, Rachel Cossetti, Carla Rameri A. S. De Azevedo, Allex Jardim da Fonseca, Yeni Nerón, João Nunes, André Lopes, Felipe Thomé, Renato Leal, Giuliano Borges, Paulo Ricardo Santos Nunes Filho, Facundo Zaffaroni, Leissa Hertzog, Rafaela Gomes de Jesus, Gustavo Werutsky e Fernando Maluf.

Prospective epidemiological study of metastatic Non-Small Cell Lung Cancer (NSCLC) in Latin America - LATINO Lung (LACOG 0116)

WCLC 2019; EP1.16-39, e-poster

Gustavo Werutsky, Andres Cardona, Diego Lucas Kaen, Oscar Arrieta, Ana Caroline Zimmer Gelatti, Clarissa Mathias, Mauro Zukin, Eduardo Cronemberger, Eldsamira Mascarenhas, Clodoaldo Campos, Vladimir Lima, Giuliano Borges, Juliano Coelho, Fernando Oliveira, Adriano Silva, Luiz Henrique Araújo, Alicia Quiroba, Helena de Andrade, Igor Morbeck, Jose Lobaton, Josiane Dias, Juan Zarba, Luis Fein, Pamela Salman, Raúl Trejo, Carlos Barrios.

Comprehensive genomic profiling of non-small cell lung cancer in Brazil (GBOT 0118/LACOG 0418).

WCLC 2019; P1.09-02, poster

S. Mascarenhas, A. Gelatti, V. De Lima, L.H. Araújo, C. Baldotto, C. Mathias, M. Zukin, G. Werutsky, P.R. Nunes Filho, R. Gomes, G. Castro.

Generating Real World Data of Breast Cancer in Brazil: validation of AMAZONA III results with cancer registries

SBOC 2019; 87510, poster

Gustavo Werutsky, Daniela Dornelles Rosa, Sergio D. Simon, José Bines, Carlos Sampaio, Alessandra Morelle, Eduardo Cronemberger, Geraldo Queiroz, Vanessa Nascimento, Rodrigo Rol, Rafaela Gomes, Carlos Barrios.

Prevalence of patients with indication of genetic evaluation for hereditary breast and ovarian syndrome in the Brazilian cohort study - AMAZONA III

SABCS 2019; P2-09-11, poster

Alessandra Borba Anton de Souza, Daniela Rosa, Antonio Luiz Frasson, Felipe Pereira Zerwes, Nathalia Cunha Rossato, Patricia Asthon-Prolla, Sergio Simon, Jose Bines, Carlos Barrios, Alessandra Morelle, Carlos Alberto Sampaio Filho, Max Mano, Rafaela Gomes and Gustavo Werutsky.

ESR1 mutations are not a mechanism of primary resistance to aromatase inhibitors in ER- positive breast cancer treated with neoadjuvant endocrine therapy.

SABCS 2019; P2-11-08, poster

Tomas Reinert, Susana Ramalho, Vivian CA Vasconcelos, Leonardo R Silva, Ana Elisa R Silva, Camila A Andrade, Maria Beatriz PL Kraft, Guilherme P Coelho, Jovana Mandelli, Monique Binotto, Cesar Cabello, Geisilene RP Silva, Jose Bines, Carlos H Barrios, Matthew J Ellis and Marcia S Graudenz.

19

CONFERENCES AND EVENTS

LACOG-GBECAM 2019 AND BEST OF SABCS

LACOG and GBECAM promoted on 29-30 March 2019 in São Paulo, Brazil, the Brazilian Breast Cancer Conference - Best of SABCS. The event had more than 600 participants and 33 speakers specialized in breast cancer.

The conference program comprised the advances of breast cancer treatment and a session of selected abstracts from SABCS 2018, which is considered one of the most important conference for clinical and translational research in breast cancer in the world.



BEST OF ASCO 2019

LACOG promoted on June 14-15, 2019, for the sixth consecutive year, the event Best of ASCO Brazil 2019, in the Transamérica Hotel in São Paulo, Brazil. The most important oncology event in the world – ASCO Annual Meeting 2019, which was held from May 31 to June 4 in Chicago, gathered more than 40.000 oncology professionals from all over the world to present and discuss the most recent researches and advances in cancer diagnosis and treatment.

LACOG is part of a select group of institutions in the world that organizes an event officially licensed by ASCO – Best of ASCO – in which oncology specialists from Brazil present studies from ASCO Annual Meeting and discuss their impact in clinical practice. The event had more than 700 participants from Argentina, Brazil, Chile, Peru and Mexico. Currently, the event Best of ASCO, organized by LACOG, is one of the most important scientific events in Brazil.



INNOVATION ONCOLOGY FORUM

LACOG, together with Tummi App Ltda, with the support of Unisinos, organized on September 28, 2019, the Innovation and Future Oncology Forum. The Forum presented innovations already available for use in Oncology, as well as the future perspectives of such specialty, opening space for discussion among doctors, managers, nurses, pharmacists, IT professions regarding the 4th Industrial Revolution and new business models in health services



GBOT NATIONAL SYMPOSIUM

The Brazilian Group of Thoracic Oncology [Grupo Brasileiro de Oncologia Torácica (GBOT)] promoted the scientific event “GBOT Symposium 2019 - Update on Lung Cancer”. This traditional event aims to discuss the main advances in lung cancer diagnosis and treatment, as well as the latest evidence on tumor markers and development of new drugs. The GBOT Symposium 2019 was held on November 08-09, 2019, at Intercontinental Hotel in São Paulo, Brazil, and had the presence of renowned national and international speakers, besides an audience of clinical oncologists, thoracic surgeons, radiation oncologists, pulmonologists, pathologists and other professionals.



II GBCP SYMPOSIUM

The LACOG Head and Neck group and the GBCP organized on November 23, 2019, the “II GBCP/LACOG National Symposium – Treatment of Head and Neck Tumors in Brazil: from ideal to real”. The event, at the Intercontinental Hotel in São Paulo, had approximately 120 participants and representatives of important institutions from Brazil, and promoted a discussion to develop guidelines of head and neck cancer treatment.



GU REVIEW

The LACOG Genitourinary Group organized the III International Symposium GU Review 2019 – LACOG. The event was held on November 29-30, 2019 in the Intercontinental Hotel, São Paulo, Brazil. The aim of the event was to deliver a comprehensive overview of all the practice-changing new data in GU cancer. In this edition the I Brazilian Consensus on Penile Cancer was developed. Specialists in the field discussed and defined essential standards for the optimal management of patients with penile cancer in Brazil.



20

THE CURE PROJECT



The Cure Project (Projeto Cura), set up by LACOG (Latin American Cooperative Oncology Group), encourages oncological research by launching the Renata Thormann Procianoy Award

Established by “The Cure Project”, the Renata Thormann Procianoy Award intends to create a culture of philanthropy, raise funds to support scientific research and encourage young oncologists to conduct research that helps in the search for a cure for cancer. The award was launched during the Best of ASCO (American Society of Clinical Oncology) congress, which was held on 14-15 June 2019 in São Paulo, Brazil. For its first edition, papers submitted to the 2019 ASCO Annual Meeting were taken into consideration for the award. A scientific committee composed of research physicians associated with LACOG selected the work submitted by Dr Thiago Bueno as the winner. Dr Thiago Bueno works in one of the leading hospitals in Brazil, the Antonio Prudente Foundation, also known as Hospital AC Camargo. More information about Dr Thiago Bueno's work can be found at projetocura.org.

The award was inspired by Nora Thormann Procianoy, who could count on the help of her daughter Renata Thormann Procianoy to support research that helped diagnose the problem she was facing with her breast prosthesis. Renata quit all her activities and dedicated herself solely to this mission. Two years later, this resulted in the inclusion of Nora's case in research coordinated by Dr Roberto Miranda at the MD Anderson Hospital, University of Texas, USA. Thanks to this research, the issue was detected and Nora could be treated. Some years later, when Nora totally recovered from the cancer, her daughter was killed in a car accident. The family decided to transform pain into love by supporting research aimed at finding a cure for cancer. Through “The Cure Project”, they donated funds to LACOG.



“JAZZ TO SUPPORT ONCOLOGY RESEARCH” BRINGS TOGETHER THE MEDICAL COMMUNITY AND MEMBERS OF THE GENERAL PUBLIC

The evening of 14 June was marked by good music and solidarity. Participants of the 2019 Best of ASCO and members of the general public joined the event “Jazz to Support Oncology Research” with maestro Osmar Barutti and singer Alba Santos. The event also included the announcement of the winner of the first Renata Thormann Procianoy Award for Oncology Research, Dr. Thiago Bueno. The creation of a philanthropy culture, raising funds to support scientific research and encouraging young oncologists to develop research that helps with finding a cure for cancer are among the objectives of the award created by “The Cure Project”. The show was held at the Blue Note in the city of São Paulo, with the support of Armazem Entretenimento.



LACOG – CURA PROJECT READY FOR CHRISTMAS EVENT

Hosted on December 13, in the city of Miami - FL, the important Christmas Show for CURA Project.

The Ready For Christmas event took place in partnership during the Journey Through Brazilian Experience event, a cultural activity of the Consulate General of Brazil in Miami, and included performances by the great Venezuelan singer-songwriter MARGER, accompanied by Puerto Rican pianist and conductor JOSE NEGRONI and his jazz band, that has been nominated 3 times for the Latin Grammy.

The show was in benefit of “Projeto Cura” in which proceeds go towards the battle against cancer and research through music and art.

“The event was attended by an audience of 250 people, representing several Latin American countries and Caribe (Venezuelans, Colombians, Mexicans, Peruvians, Argentines, Brazilians, Cubans, Puerto Ricans, etc.). We also had the presence of Dr Orlando Silva, Medical Oncologist in Miami and scientific director of CURA and Dr Luis Fernando Luis Fernando Correia, Md, journalist and CURA Ambassador.”





LACOG
LATIN AMERICAN
COOPERATIVE
ONCOLOGY GROUP